CUMBERLAND PHARMACEUTICALS INC
For the period ended Jun 30, 2026. Filed Aug 7, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Jun 30, 2026 · Filed Aug 7, 2026
CPIX$5.30-1.3%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Operations
| Three months ended June 30, | Six months ended June 30, | |||
|---|---|---|---|---|
| 2026 | 2025 | 2026 | 2025 | |
| Net revenues from continuing operations | $166,458 | $380,797 | $330,308 | $547,425 |
| Costs and expenses: | ||||
| Research and development | 772,162 | 837,401 | 1,538,007 | 1,522,188 |
| General and administrative | 2,547,606 | 2,657,146 | 4,870,980 | 4,855,889 |
| Amortization | 7,151 | 5,769 | 14,152 | 11,844 |
| Total costs and expenses | 3,326,919 | 3,500,316 | 6,423,139 | 6,389,921 |
| Operating loss | (3,160,461) | (3,119,519) | (6,092,831) | (5,842,496) |
| Interest income | 60,884 | 127,489 | 138,915 | 253,198 |
| Interest expense | (724) | (471) | (790) | (4,863) |
| Loss before income taxes | (3,100,301) | (2,992,501) | (5,954,706) | (5,594,161) |
| Income tax expense | (3,870) | (5,671) | (7,741) | (11,341) |
| Net loss from continuing operations | (3,104,171) | (2,998,172) | (5,962,447) | (5,605,502) |
| Net income (loss) from discontinued operations | (1,170,259) | 2,262,965 | (1,599,034) | 6,118,479 |
| Net income (loss) | (4,274,430) | (735,207) | (7,561,481) | 512,977 |
| Net income (loss) at subsidiary attributable to noncontrolling interests | (1,947) | (5,533) | (4,535) | 3,351 |
| Net income (loss) attributable to common shareholders | $(4,276,377) | $(740,740) | $(7,566,016) | $516,328 |
| Income (loss) per share attributable to common shareholders | ||||
| - Continuing operations - basic | $(0.21) | $(0.20) | $(0.40) | $(0.37) |
| - Discontinued operations - basic | (0.08) | 0.15 | (0.11) | 0.41 |
| $(0.29) | $(0.05) | $(0.51) | $0.03 | |
| - Continuing operations - diluted | $(0.21) | $(0.20) | $(0.40) | $(0.37) |
| - Discontinued operations - diluted | (0.08) | 0.15 | (0.11) | 0.41 |
| $(0.29) | $(0.05) | $(0.51) | $0.03 | |
| Weighted-average shares outstanding | ||||
| - basic | 14,981,607 | 14,960,596 | 14,970,968 | 14,951,609 |
| - diluted | 14,981,607 | 14,960,596 | 14,970,968 | 14,951,609 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.